Adaptimmune
Philadelphia, PA 19112
At a Glance
- Primary NAICS Code
- 541714
- Headquarters
- Philadelphia, PA
- UEI
- VMSVCL9NTHJ9
- CAGE
- 9P3M2
About
Adaptimmune focuses on designing and delivering novel cancer immunotherapy products, specifically T-cell receptor (TCR) T-cell therapies. The company utilizes a proprietary TCR platform to identify cancer targets and genetically engineer TCRs to recognize and attack these targets, producing autologous T-cell treatments. Adaptimmune has a preclinical pipeline with multiple cell therapy approaches and manufactures products at its Navy Yard facility in Philadelphia, PA.
Capabilities & Markets
Directory supply chains
Products
Manufacturing processes
End markets served
Classification
NAICS Codes
Compliance & Registrations
Registration IDs
- UEI
- VMSVCL9NTHJ9
- CAGE
- 9P3M2
Related Manufacturers
Qrono IncQrono Inc. is developing immunotherapies using the Eloquent platform to target antigen-presenting cells and macrophages for cancer treatment. The company focuses on mathematically optimized polymer particles to deliver agents at controlled rates to specific cells.PITTSBURGH, PA
Churchill PharmaceuticalsChurchill Pharmaceuticals is focused on developing and delivering valued therapies that improve trusted pharmaceuticals for patients living with cancer. The company is a rapidly growing, privately funded company based in the greater Philadelphia area with a lead product for genitourinary cancers and a pipeline including oral cancer compounds utilizing SoluMatrix Fine Particle Technology®.KING OF PRUSSIA, PA
NovocureNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. The company's commercialized products are approved for treating adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma.PORTSMOUTH, NH
Tavotek BiotherapeuticsTavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company leverages proprietary antibody engineering platforms to generate high-affinity, high-specificity antibodies targeting disease-relevant antigens in Oncology and Immunology.LOWER GWYNEDD, PA